Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06668493 · ClinicalTrials.gov registry record · Phase 1
Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis
A Phase 1 study of Low-grade Upper Tract Urothelial Carcinoma, sponsored by Ferring Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 7
- Study locations
NCT06668493 is a Phase 1 study of Low-grade Upper Tract Urothelial Carcinoma that is actively recruiting participants, run by Ferring Pharmaceuticals. The registered enrollment target is 20 participants. The trial reports 7 study locations across 7 states.
The verdict
NCT06668493, a Phase 1 study of Low-grade Upper Tract Urothelial Carcinoma, is actively recruiting participants, sponsored by Ferring Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 7
- Study locations
Study Summary
The primary purpose of this trial is to evaluate the safety \& tolerability of Nadofaragene Firadenovec in subjects with LG-UTUC. To help with this evaluation, a safety lead-in period will be conducted for the first 6 subjects. Complete response is at 3 or 6 months defined as absence of any UTUC in the renal pelvis.
Conditions Studied
Interventions
- DRUG Nadofaragene Firadenovec
Study Locations (7)
Arizona
- Mayo Clinic - Scottsdale Arizona - Scottsdale
Florida
- Mayo Clinic - Jacksonville
Indiana
- Indiana University - Indianapolis
Minnesota
- Mayo Clinic - Rochester Minnesota - Rochester
New York
- Memorial Sloan Kettering Cancer Center - New York
Pennsylvania
- University of Pennsylvania - Perelman Center for Advanced Medicine - Penn Urology - Philadelphia
Texas
- MD Anderson Cancer Center - Genitourinary (GU) Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-06-12 |
| Est. Completion | 2029-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06668493
The ClinicalTrials.gov registry entry for NCT06668493 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Low-grade Upper Tract Urothelial Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Nadofaragene Firadenovec is the first listed.
NCT06668493 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Arizona, Florida, Indiana.
Frequently Asked Questions
What is clinical trial NCT06668493 about?
NCT06668493 is a clinical study titled "Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis". The primary purpose of this trial is to evaluate the safety \& tolerability of Nadofaragene Firadenovec in subjects with LG-UTUC. To help with this evaluation, a safety lead-in period will be conducted for the first 6 subjects. Complete response is at 3 or 6 months defined as absence of any UTUC in ...
What is the current status of trial NCT06668493?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-06-12. Estimated completion is 2029-11-30.
What conditions does trial NCT06668493 study?
This clinical trial studies the following conditions: Low-grade Upper Tract Urothelial Carcinoma.
What interventions are being tested in trial NCT06668493?
The interventions under investigation include: Nadofaragene Firadenovec (DRUG).
Who is sponsoring clinical trial NCT06668493?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06668493 being conducted?
This trial has 7 study locations across Arizona, Florida, Indiana, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Low-grade Upper Tract Urothelial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.